SLP - Simulations Plus, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
18.80
-0.20 (-1.05%)
At close: 4:00PM EDT

18.80 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close19.00
Open19.05
Bid18.65 x 1200
Ask20.00 x 900
Day's Range18.80 - 19.25
52 Week Range11.45 - 19.55
Volume61,402
Avg. Volume53,641
Market Cap325.729M
Beta-1.00
PE Ratio (TTM)39.92
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.24 (1.36%)
Ex-Dividend Date2018-04-24
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire6 days ago

    Simulations Plus to Present at the Needham Emerging Technology Conference on May 16, 2018

    Simulations Plus, Inc. (SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today announced that chairman and chief executive officer, Walt Woltosz, will present at the Needham Emerging Technology Conference on Wednesday, May 16, 2018, at 3:00 p.m. ET and will conduct one-on-one meetings throughout the day. Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents.

  • Business Wire13 days ago

    US FDA Procures DILIsym Software License Package

    DILIsym Services, Inc., a Simulations Plus company (SLP) and a leading provider of simulation and modeling software for pharmaceutical safety, today announced that the U.S. Food and Drug Administration has secured an annual government license for its flagship QSP (quantitative systems pharmacology) modeling software, DILIsym®. DILIsym is the product of an ongoing public-private partnership (the DILI-sim Initiative – www.DILIsym.com) that involves scientists from the pharmaceutical industry, academia and the FDA. The use of modeling and simulation tools like DILIsym is being promoted by FDA Commissioner Dr. Scott Gottlieb to improve the efficiency of drug development (https://blogs.fda.gov/fdavoice/index.php/2017/06/fostering-medical-innovation-a-plan-for-digital-health-devices/).

  • ACCESSWIRElast month

    EX-Dividend Schedule: Simulations Plus Has a Dividend Yield of 1.38%; Will Trade Ex-Dividend on April 24, 2018

    LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors has a free review on Simulations Plus, Inc. (NASDAQ: SLP) following the Company's announcement that it will begin trading ex-dividend on April 24, 2018. Active-Investors has initiated due-diligence on this dividend stock. If your portfolio includes dividend stocks, you have come to the right place for timely information.

  • Business Wirelast month

    Simulations Plus Reports Record Second Quarter FY2018 Revenue

    Simulations Plus, Inc. , the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its second quarter of fiscal year 2018, the period ended February 28, 2018 .

  • ACCESSWIRElast month

    Simulations Plus, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 9, 2018 / Simulations Plus, Inc. (NASDAQ: SLP ) will be discussing their earnings results in their Q2 Earnings Call to be held on April 9, 2018, at 4:15 PM Eastern Time. ...

  • Business Wire2 months ago

    Simulations Plus Sets Date for 2nd Quarter 2018 Earnings Release and Conference Call

    Simulations Plus, Inc. announced today that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2018 fiscal year, the period ended February 28, 2018, on Monday, April 9, 2018.

  • Business Wire4 months ago

    Simulations Plus Launches Version 2.0 of PKPlus™

    Simulations Plus, Inc. , the premier provider of simulation and modeling software and consulting services for pharmaceutical development from earliest discovery through all phases of clinical trials, today announced the launch of version 2.0 of PKPlus, a major update to its software for analysis of preclinical and clinical trial data.

  • Business Wire4 months ago

    Simulations Plus Subsidiary Cognigen Releases KIWI Version 2

    Cognigen Corporation, a Simulations Plus company and a leading provider of population pharmacokinetic and pharmacodynamic modeling and simulation services, today announced that it has released Version 2 of its KIWI™ Pharmacometric Communication and Collaboration Platform.

  • ACCESSWIRE4 months ago

    EX-Dividend Schedule: Simulations Plus Has a Dividend Yield of 1.47%; Will Trade Ex-Dividend on January 25, 2018

    LONDON, UK / ACCESSWIRE / January 24, 2018 / Active-Investors has a free review on Simulations Plus, Inc. (NASDAQ: SLP ) following the Company's announcement that it will begin trading ex-dividend on January ...

  • Business Wire4 months ago

    Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share

    Simulations Plus, Inc. , the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.06 per share to its shareholders.

  • ACCESSWIRE4 months ago

    Free Post Earnings Research Report: Bandwidth’s Revenue Grew 7%; Beats Expectations

    Stock Monitor: Simulations Plus Post Earnings Reporting LONDON, UK / ACCESSWIRE / January 16, 2018 / Active-Investors.com has just released a free earnings report on Bandwidth Inc. (NASDAQ: BAND ). If ...

  • Business Wire4 months ago

    DILIsym Services Inc., a Simulations Plus Company, Releases DILIsym® Version 7A

    DILIsym Service, Inc., a Simulations Plus company and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it has released Version 7A of its flagship QSP modeling program, DILIsym®.

  • Business Wire4 months ago

    Simulations Plus Reports First Quarter FY2018 Financial Results

    Simulations Plus, Inc. , the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its first quarter of fiscal year 2018, the period ended November 30, 2017 .

  • Business Wire5 months ago

    Simulations Plus Sets Date for 1st Quarter 2018 Earnings Release and Conference Call

    Simulations Plus, Inc. announced today that it expects to file its quarterly report on Form 10-Q for the first quarter of its 2018 fiscal year on Tuesday, January 9, 2018.

  • ACCESSWIRE5 months ago

    Wildfire Forces Cancellation of LD Micro Conference

    Presentations Canceled for Celsius Holdings, Inc., GSI Technology, Inc., PCM, Inc., Simulations-Plus, ADOMANI, Inc., HUTN, Inc., NanoVibronix, Inc. and WidePoint Corp. NEW YORK, NY / ACCESSWIRE / December ...

  • Business Wire6 months ago

    Simulations Plus Releases ADMET Predictor™ Version 8.5

    Simulations Plus, Inc. , a leading provider of modeling and simulation solutions for the pharmaceutical, chemicals, and consumer goods industries, today announced that it has released version 8.5 of its best-in-class molecular property prediction program, ADMET Predictor™.

  • Business Wire6 months ago

    Simulations Plus to Present at LD Micro 10th Annual Main Event on December 6

    Simulations Plus, Inc. , a leading provider of software for pharmaceutical discovery and development, today announced that chairman and chief executive officer, Walt Woltosz, will present at the 10th annual LD Micro Main Event at 4 p.m.

  • Business Wire6 months ago

    Simulations Plus Reports FY2017 and Fourth Quarter FY2017 Financial Results

    Simulations Plus, Inc. , a leading provider of software for pharmaceutical discovery and development, today reported its financial results for its 2017 fiscal year and fourth quarter ended August 31, 2017.

  • ACCESSWIRE6 months ago

    Simulations Plus Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 14, 2017 / Simulations Plus Inc. (NASDAQ: SLP ) will be discussing their earnings results in their Q4 Earnings Call to be held on Tuesday, November 14, 2017, at 4:15 ...

  • Business Wire6 months ago

    Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2017 Earnings Release and Conference Call

    Simulations Plus, Inc. announced today that it expects to file Form 10-K for the 2017 fiscal year ended August 31, 2017, with the U.S. Securities and Exchange Commission on November 14, 2017.

  • Business Wire8 months ago

    Simulations Plus Reports Preliminary Revenues for Fourth Quarter and Fiscal Year 2017

    Simulations Plus, Inc. , the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today released preliminary revenues for its fiscal fourth quarter and full fiscal year 2017 ended August 31, 2017.

  • Business Wire9 months ago

    Simulations Plus Announces Senior Management Changes

    Simulations Plus, Inc. , a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced changes in its senior management structure.

  • Business Wire9 months ago

    Simulations Plus Releases MembranePlus™ Version 2

    Simulations Plus, Inc. , a leading provider of modeling and simulation solutions for the pharmaceutical, chemicals, and consumer goods industries, today announced that it has released version 2 of its in vitro data analysis program, MembranePlus™.

  • Business Wire9 months ago

    DILIsym Services Inc., a Simulations Plus Company, Releases DILIsym® Version 6A

    DILIsym Services Inc., a Simulations Plus company and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it has released Version 6A of its flagship QSP modeling program, DILIsym.